Cargando…

Screening for onconeural antibodies in neuromyelitis optica spectrum disorders

BACKGROUND: Some so-called “non-classical” paraneoplastic neurological syndromes (PNS), namely optic neuritis and myelitis, clinically overlap with neuromyelitis optica spectrum disorders (NMOSD), and conversely, in cancer-associated NMOSD, a paraneoplastic etiology has been suggested in rare cases....

Descripción completa

Detalles Bibliográficos
Autores principales: Berger, Benjamin, Hottenrott, Tilman, Rauer, Sebastian, Stich, Oliver
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5223419/
https://www.ncbi.nlm.nih.gov/pubmed/28068933
http://dx.doi.org/10.1186/s12883-016-0779-9
_version_ 1782493167710371840
author Berger, Benjamin
Hottenrott, Tilman
Rauer, Sebastian
Stich, Oliver
author_facet Berger, Benjamin
Hottenrott, Tilman
Rauer, Sebastian
Stich, Oliver
author_sort Berger, Benjamin
collection PubMed
description BACKGROUND: Some so-called “non-classical” paraneoplastic neurological syndromes (PNS), namely optic neuritis and myelitis, clinically overlap with neuromyelitis optica spectrum disorders (NMOSD), and conversely, in cancer-associated NMOSD, a paraneoplastic etiology has been suggested in rare cases. Therefore, we retrospectively investigated the prevalence of onconeural antibodies, which are highly predictive for a paraneoplastic etiology, and the prevalence of malignancies in NMOSD patients. METHODS: We retrospectively screened 23 consecutive patients from our clinic with NMOSD (13 were anti-aquaporin-4 [AQP4] antibody positive, 10 were AQP4 negative) for onconeural antibodies using an immunoblot. RESULTS: All patients were negative for a broad spectrum of antibodies targeting intracellular onconeural antigens (Hu, Yo, Ri, CV2/CRMP5, Ma1, Ma2, Zic4, SOX1, Tr, and amphiphysin). Notably, only two patients had a malignancy. However, neoplastic entities (astrocytic brain tumor and acute myeloid leukemia) were not typical for PNS. CONCLUSIONS: Our data suggest that there is no need to routinely screen anti-AQP4 antibody positive NMOSD patients with a typical presentation for onconeural antibodies. Furthermore, absence of these antibodies in NMOSD, which is typically non-paraneoplastic, confirms their high specificity for PNS.
format Online
Article
Text
id pubmed-5223419
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-52234192017-01-11 Screening for onconeural antibodies in neuromyelitis optica spectrum disorders Berger, Benjamin Hottenrott, Tilman Rauer, Sebastian Stich, Oliver BMC Neurol Research Article BACKGROUND: Some so-called “non-classical” paraneoplastic neurological syndromes (PNS), namely optic neuritis and myelitis, clinically overlap with neuromyelitis optica spectrum disorders (NMOSD), and conversely, in cancer-associated NMOSD, a paraneoplastic etiology has been suggested in rare cases. Therefore, we retrospectively investigated the prevalence of onconeural antibodies, which are highly predictive for a paraneoplastic etiology, and the prevalence of malignancies in NMOSD patients. METHODS: We retrospectively screened 23 consecutive patients from our clinic with NMOSD (13 were anti-aquaporin-4 [AQP4] antibody positive, 10 were AQP4 negative) for onconeural antibodies using an immunoblot. RESULTS: All patients were negative for a broad spectrum of antibodies targeting intracellular onconeural antigens (Hu, Yo, Ri, CV2/CRMP5, Ma1, Ma2, Zic4, SOX1, Tr, and amphiphysin). Notably, only two patients had a malignancy. However, neoplastic entities (astrocytic brain tumor and acute myeloid leukemia) were not typical for PNS. CONCLUSIONS: Our data suggest that there is no need to routinely screen anti-AQP4 antibody positive NMOSD patients with a typical presentation for onconeural antibodies. Furthermore, absence of these antibodies in NMOSD, which is typically non-paraneoplastic, confirms their high specificity for PNS. BioMed Central 2017-01-10 /pmc/articles/PMC5223419/ /pubmed/28068933 http://dx.doi.org/10.1186/s12883-016-0779-9 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Berger, Benjamin
Hottenrott, Tilman
Rauer, Sebastian
Stich, Oliver
Screening for onconeural antibodies in neuromyelitis optica spectrum disorders
title Screening for onconeural antibodies in neuromyelitis optica spectrum disorders
title_full Screening for onconeural antibodies in neuromyelitis optica spectrum disorders
title_fullStr Screening for onconeural antibodies in neuromyelitis optica spectrum disorders
title_full_unstemmed Screening for onconeural antibodies in neuromyelitis optica spectrum disorders
title_short Screening for onconeural antibodies in neuromyelitis optica spectrum disorders
title_sort screening for onconeural antibodies in neuromyelitis optica spectrum disorders
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5223419/
https://www.ncbi.nlm.nih.gov/pubmed/28068933
http://dx.doi.org/10.1186/s12883-016-0779-9
work_keys_str_mv AT bergerbenjamin screeningforonconeuralantibodiesinneuromyelitisopticaspectrumdisorders
AT hottenrotttilman screeningforonconeuralantibodiesinneuromyelitisopticaspectrumdisorders
AT rauersebastian screeningforonconeuralantibodiesinneuromyelitisopticaspectrumdisorders
AT sticholiver screeningforonconeuralantibodiesinneuromyelitisopticaspectrumdisorders